Skip to main content

The independent medical news service

19-02-2020 | Oncology | News | Article

COSMIC-021: Cabozantinib–atezolizumab duo promising for mCRPC

The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.

14-02-2020 | Oncology | News | Article

CARD: Favorable metastatic CRPC PROs observed with cabazitaxel

The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.

14-02-2020 | Oncology | News | Article

Long-term CHHiP data further support hypofractionated radiotherapy for prostate cancer

The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.

14-02-2020 | Oncology | News | Article

​​​​​​​STOMP 5-year results confirm potential of metastasis-directed therapy in prostate cancer

Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.

11-02-2020 | Oncology | News | Article

Incorporating genetic risk may help personalize prostate cancer screening strategies

Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.

04-02-2020 | Oncology | Highlight | News

Darolutamide receives positive EMA decision for nonmetastatic CRPC

Click through for more information